Back to News
Market Impact: 0.12

SCHD Offers a Higher Yield While FDVV Grows Faster

CSCOAMGNNVDAMSFTAAPL
Capital Returns (Dividends / Buybacks)Technology & InnovationCompany FundamentalsMarket Technicals & FlowsInvestor Sentiment & PositioningAnalyst Insights
SCHD Offers a Higher Yield While FDVV Grows Faster

The piece compares Fidelity's FDVV and Schwab's SCHD dividend ETFs, highlighting key differences: SCHD charges a 0.06% expense ratio vs. FDVV's 0.15%, yields 3.7% vs. 3.0%, and holds about $73 billion AUM (nearly ten times FDVV). Over the past year (as of Dec. 16, 2025) FDVV returned 10.3% versus SCHD's -1.4%, while five-year growth of $1,000 favored FDVV ($1,757) over SCHD ($1,285); five-year max drawdowns were shallower for SCHD (‑16.8% vs. ‑20.2%). Sector and holdings contrast drives the tradeoffs: FDVV tilts to tech (26%) with top holdings like Nvidia, Microsoft and Apple for growth, while SCHD emphasizes energy, consumer staples and healthcare with holdings such as Merck, Cisco and Amgen for higher yield and lower cost, suggesting income-focused investors may prefer SCHD and growth-oriented investors FDVV.

Analysis

Market structure: SCHD’s scale (≈$73bn) and 0.06% fee make it the low-cost, high-yield incumbent for income buyers; FDVV’s tech tilt (NVDA/MSFT/AAPL ~largest weights) benefits when growth leadership resumes. Winner cohorts: low-vol income allocators (SCHD) and growth-biased dividend seekers (FDVV); losers are mid-cap high-yield strategies that can’t match SCHD’s liquidity or FDVV’s tech exposure. Net effect: marginal inflows to FDVV would bid mega-cap techs and raise option skew; large SCHD inflows compress yield spreads versus corporates. Risk assessment: Tail risks include a >=25% correction in mega-cap tech (hits FDVV, given NVDA weight), large dividend cuts in energy/MLT sectors (pressure SCHD), or a 75–100bp unexpected Fed hiking impulse that re-prices yield equities in 1–3 months. Short-term (days–weeks) price moves will be flow-driven around earnings/Fed; medium-term (3–9 months) performance depends on tech earnings and oil/healthcare dividend announcements; long-term (1–3 years) expense ratio and dividend growth drive net returns. Hidden dependency: FDVV’s recent outperformance is concentrated in few names (NVDA/MSFT); patient mean-reversion in mega-caps would materially compress FDVV alpha. Trade implications: Tactical: use volatility and concentration to express asymmetry — defined‑risk long call spreads on NVDA/MSFT (9–12m) to capture growth tilt while avoiding single-stock outright. Core income: overweight SCHD (2–4% portfolio) for steady yield and lower drawdown; fund covered-call overlays to lift yield. Relative-value: pair trades long FDVV / short SCHD (matched dollar beta) for a 3–9 month tactical rotation into growth, closed on 300–500bp spread reversion or 40% move in NVDA. Contrarian angles: Consensus underestimates SCHD’s protective value in a volatility selloff because its dividend-screened index reduces downside (historical 5y drawdown -16.8% vs FDVV -20.2%). Conversely FDVV’s 1‑yr outperformance is likely concentrated—if NVDA/MSFT contributions revert, FDVV may lag materially despite higher short-term returns. Historical parallel: 2018–2019 tech-led divergence reversed when breadth improved; similar mean-reversion risk exists here. Unintended consequence: heavy rotation into FDVV could increase liquidity/option stress on mega-caps, amplifying drawdowns during sell-offs.